Referrals to Vivos’ Las Vegas sleep centers rose about threefold. Added revenue is expected in Q4.
Vivos Therapeutics (VVOS) reported a threefold increase in referrals to its Las Vegas sleep centers, expecting Q4 revenue growth. The company targets $3.6M in annual savings by Q4 2026 and projects $1.5M-$3.0M from EEG initiatives, $3.5M from remote monitoring by Q1 2027, and $2.4M-$5.6M from payer contract renegotiations. Management aims for positive cash flow by late 2026 and profitability in 2027.
How this was made
The 30-second read
Why it matters
The company aims for positive cash flow by late 2026 and profitability in 2027, signaling a turnaround that could attract value‑oriented investors.
Market read
First‑time disclosure of a restructuring plan with modest financial impact; may trigger short‑term price appreciation for VVOS.
What to watch
Potential regulatory scrutiny of new EEG testing services and competition from larger sleep‑apnea device makers.
Background
Vivos Therapeutics (Nasdaq: VVOS) issued a press release outlining restructuring, cost reductions, and new revenue initiatives after a period of flat earnings.
Ticker impact
Vivos Therapeutics disclosed a restructuring plan targeting $3.6 M annual overhead savings and new revenue streams (EEG, remote monitoring, payer rate hikes) expected to begin Q4 2026.
likely modest upside as investors price in higher cash flow and profit potential
Guidance adds $7‑12 M of incremental revenue and $3.6 M of cost savings, a material shift for a micro‑cap, but absolute dollar size remains modest.
Market effects
Highlights growing demand for sleep‑apnea diagnostics and remote‑patient monitoring, potentially benefitting peers in the sleep‑technology space.
Limited to U.S. healthcare and med‑tech investors; no broader regional effect.
Minimal global impact; primarily a micro‑cap specific development.
Counterpoint
The revenue forecasts rely on payer contract renegotiations that may face delays, and the cost‑saving timeline could slip, limiting upside.
Key entities
- companyVivos Therapeutics, Inc.
Medical device and healthcare services firm focused on obstructive sleep apnea treatments.
- executiveR. Kirk Huntsman
Chairman and CEO of Vivos Therapeutics.


